This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

For patients requiring treatment of infections due to resistant, aerobic Gram-negative bacteria

ZAVICEFTA®: A combination of ceftazidime and avibactam1

Avibactam is a novel β-lactamase inhibitor combined with ceftazidime, a cephalosporin with established clinical experience2​​​​​​​

ZAVICEFTA: Potent inhibitory activity against difficult-to-treat infections due to aerobic Gram-negative bacteria​​​​​​​1,2

Avibactam inhibits both Ambler class A and class C β-lactamases and some class D enzymes, including1*:
•    ESBLs
•    KPCs
•    OXA-48 carbapenemases
•    AmpC enzymes

Contact us

** This is an optional area where footnotes can live.

*Avibactam does not inhibit class B enzyme​​​​​​​s (metallo-β-lactamases) and is not able to inhibit many class D enzymes1.

ZAVICEFTA is effective against infections with Enterobacteriaceae and P. aeruginosa with EUCAST minimum inhibitory concentrations as follows1:

Organisms

Susceptible

Resistant

Enterobacteriaceae

≤ 8 mg/L

> 8 mg/L

P. aeruginosa

≤ 8 mg/L

> 8 mg/L

Explore more

Pathogen coverage

ZAVICEFTA has broad spectrum coverage against Gram-negative pathogens including in vitro activity against MDR P.aeruginosa, CRE, including KPC- and OXA-48 producing strains, and ESBL- and AmpC-producing bacteria1-4.

Read more

Patient Risk factors

Identifying patients at risk of MDR Gram-negative infections is vital for appropriate selection of adequate, early antimicrobial therapy to reduce the risk of fatal outcomes5.

Read more


Abbreviations:​​​​​​​

​​​​​​​cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; CrCl, creatinine clearance; ELF, epithelial lining fluid; AMR, Antimicrobial Resistance; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing;

References
  1. ZAVICEFTA. Summary of Product Characteristics
  2. Liscio JL, et al. Int J Antimicrob Agents 2015;46:266–71
  3. Nicolau DP, et al. J Antimicrob Chemother 2015;70:2862–9
  4. Mazuski JE, et al. Surg Infect 2017;18:1–76
  5. Bonine NG, et al. Am J Med Sci 2019;357:102–10
PP-ZVA-GBR-0837. June 2021

Learn more about ZAVICEFTA’s Phase III clinical trials in adult patients with cUTI, cIAI and HAP/VAP.

Learn more about efficacy

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

ZAVICEFTA’ s indications and its role in clinical practice

Dr Matthew Dryden, Consultant Microbiologist at Hampshire Hospitals presents ZAVICEFTA’ s indications and its role in clinical practice. ​​

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No